Zeltia SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Zeltia SA Announces Results From Phase II Trial Of Noscira's Alzheimer's Treatment-Reuters
Reuters reported that Zeltia says results from a phase II trial of Noscira's Alzheimer's treatment did not meet the primary objective of showing an improvement. The Company added that the results suggest a need for further studies in earlier stages of the illness or for a longer treatment period.
Latest Developments for Zeltia SA
Latest Key Developments in Biotechnology
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Share this
- Digg this